Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells

The receptor tyrosine kinase inhibitor lapatinib, indicated to treat patients with HER2-positive breast cancer in combination with capecitabine, can cause severe hepatotoxicity. Lapatinib is further associated with mitochondrial toxicity and accumulation of reactive oxygen species. The effect of lap...

Descripción completa

Detalles Bibliográficos
Autores principales: Roos, Noëmi Johanna, Aliu, Diell, Bouitbir, Jamal, Krähenbühl, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339965/
https://www.ncbi.nlm.nih.gov/pubmed/32694997
http://dx.doi.org/10.3389/fphar.2020.00944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339965/
https://www.ncbi.nlm.nih.gov/pubmed/32694997
http://dx.doi.org/10.3389/fphar.2020.00944

Ejemplares similares